The safety of treatment options for pediatric Crohn’s disease

References

• Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008 Oct;135(4):1106–1113.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):168–174.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol. 2006 Sep;4(9):1124–1129.
   PubMed Web of Science ®Google Scholar
• Schaefer ME, Machan JT, Kawatu D, et al. Factors that determine risk for surgery in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2010 Sep;8(9):789–794.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000 Oct;119(4):895–902.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–765e2. quiz e14–5.
   PubMed Web of Science ®Google Scholar
• Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013 Oct;145(4):766–74e1.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–873. quiz 1165-6.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012 Aug;143(2):365–374e2.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May;4(5):621–630.
   PubMed Web of Science ®Google Scholar
• Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn’s disease. J Pediatr Gastroenterol Nutr. 1993 Aug;17(2):186–192.
   PubMed Web of Science ®Google Scholar
• Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2010;12:CD008870.
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis. Summer 1997;3(2):65–78.
   PubMed Web of Science ®Google Scholar
• Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord. Spring 2004;4(2):86–91.
   PubMedGoogle Scholar
• D’Agata ID, Vanounou T, Seidman E. Mesalamine in pediatric inflammatory bowel disease: a 10-year experience. Inflamm Bowel Dis. Winter 1996;2(4):229–235.
   PubMed Web of Science ®Google Scholar
• Moum B. Which are the 5-ASA compound side effects and how is it possible to avoid them? Inflamm Bowel Dis. 2008 Oct;14(Suppl 2):S212–S213.
   PubMed Web of Science ®Google Scholar
• Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut. 2002 Oct;51(4):536–539.
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001 Oct;33(4):289–294.
   PubMed Web of Science ®Google Scholar
• Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol. 1998 Oct;25(10):1995–2002.
   PubMed Web of Science ®Google Scholar
• Escher JC. European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol. 2004 Jan;16(1):47–54.
   PubMed Web of Science ®Google Scholar
• Levine A, Watemberg N, Hager H, et al. Benign intracranial hypertension associated with budesonide treatment in children with Crohn’s disease. J Child Neurol. 2001 Jun;16(6):458–461.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr. 1988 Aug;113(2):249–254.
   PubMed Web of Science ®Google Scholar
• Kundhal P, Zachos M, Holmes JL, et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr. 2001 Jul;33(1):75–80.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995 Feb 2;332(5):292–297.
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo in inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150:380–388.
   Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000 Jun 1;342(22):1627–1632.
   PubMed Web of Science ®Google Scholar
• Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015 Oct;13(10):1748–1756.
   PubMed Web of Science ®Google Scholar
• Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016 Jan;22(1):224–233.
   PubMed Web of Science ®Google Scholar
• Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol. 2003 Mar;98(3):530–537.
   PubMed Web of Science ®Google Scholar
• Kempinska A, Benchimol EI, Mack A, et al. Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2011 Oct;53(4):389–393.
   PubMed Web of Science ®Google Scholar
• Batres LA, Gabriel CA, Tsou VM. Methotrexate-induced esophagitis in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2003 Oct;37(4):514–516.
   PubMed Web of Science ®Google Scholar
• Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? Gut. 2012 Apr;61(4):476–483.
   PubMed Web of Science ®Google Scholar
• Fournier MR, Klein J, Minuk GY, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010 Jul;105(7):1620–1626.
   PubMed Web of Science ®Google Scholar
• Conway R, Low C, Coughlan RJ, et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015;350:h1269.
   PubMedGoogle Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014 May;66(5):1101–1110.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014 Apr;53(4):757–763.
   PubMed Web of Science ®Google Scholar
• Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998 Oct;115(4):813–821.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013 Jun;19(7):1404–1410.
   PubMed Web of Science ®Google Scholar
• Korelitz BI, Zlatanic J, Goel F, et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol. 1999 Jun;28(4):341–344.
   PubMed Web of Science ®Google Scholar
• Al Hadithy AF, De Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005 Apr;37(4):282–297.
   PubMedGoogle Scholar
• Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004 May;2(5):410–417.
   PubMed Web of Science ®Google Scholar
• Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf. 2008 Sep;7(5):607–616.
   PubMed Web of Science ®Google Scholar
• Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):775–782.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005 Jul 1;22(1):1–16.
   PubMed Web of Science ®Google Scholar
• Ledder OD, Lemberg DA, Ooi CY, et al. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? J Pediatr Gastroenterol Nutr. 2013 Nov;57(5):583–586.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis. 2004 Feb;10(Suppl 1):S35–S37.
   PubMedGoogle Scholar
• Toruner M, Loftus EV Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr;134(4):929–936.
   PubMed Web of Science ®Google Scholar
• Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010 Mar;8(3):268–274.
   PubMed Web of Science ®Google Scholar
• Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012 Aug;143(2):390–399 e1.
   PubMed Web of Science ®Google Scholar
• O’Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005 Sep 16;309(5742):1871–1874.
   PubMed Web of Science ®Google Scholar
• Imashuku S, Hlbi S, Todo S. Hemophagocytic lymphohistiocytosis in infancy and childhood. J Pediatr. 1997 Mar;130(3):352–357.
   PubMed Web of Science ®Google Scholar
• Biank VF, Sheth MK, Talano J, et al. Association of Crohn’s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr. 2011 Nov;159(5):808–812.
   PubMed Web of Science ®Google Scholar
• Virdis F, Tacci S, Messina F, et al. Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn’s disease. World J Gastrointest Surg. 2013 Nov 27;5(11):306–308.
   PubMedGoogle Scholar
• Ling YH, Chan JY, Beattie KL, et al. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol. 1992 Nov;42(5):802–807.
   PubMed Web of Science ®Google Scholar
• Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem. 2003 Jan 10;278(2):1005–1011.
   PubMed Web of Science ®Google Scholar
• Smith MA, Irving PM, Marinaki AM, et al. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010 Jul;32(2):119–130.
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005 Aug;54(8):1121–1125.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009 Nov 7;374(9701):1617–1625.
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013 Nov;145(5):1007–1015 e3. .
   PubMed Web of Science ®Google Scholar
• Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007 Aug;13(8):1024–1030.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jan;9(1):36–41e1.
   PubMed Web of Science ®Google Scholar
• Gerich ME, Yoon JL, Targan SR, et al. Long-term outcomes of thalidomide in refractory Crohn’s disease. Aliment Pharmacol Ther. 2015 Mar;41(5):429–437.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014 Oct 1;8(10):1179–1207.
   PubMed Web of Science ®Google Scholar
• Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996 Apr;22(3):296–302.
   PubMed Web of Science ®Google Scholar
• Watson S, Pensabene L, Mitchell P, et al. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011 Jan;17(1):22–29.
   PubMed Web of Science ®Google Scholar
• Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol. 2003 Apr;98(4):833–838.
   PubMed Web of Science ®Google Scholar
• Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015 Apr;21(4):783–792.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Mar;33(6):619–633.
   PubMed Web of Science ®Google Scholar
• Coffin CS, Fraser HF, Panaccione R, et al. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-alpha) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011 Jan;17(1):479–484.
   PubMed Web of Science ®Google Scholar
• Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012 Aug;36(4):312–323.
   PubMed Web of Science ®Google Scholar
• Khanna R, Feagan BG. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opin Drug Saf. 2015 Jun;14(6):987–997.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Jul;34(1):51–58.
   PubMed Web of Science ®Google Scholar
• Kip KE, Swoger JM, Grandinetti LM, et al. Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis. 2013 May;19(6):1164–1172.
   PubMed Web of Science ®Google Scholar
• Moran GW, Lim AW, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Nov;38(9):1002–1024.
   PubMed Web of Science ®Google Scholar
• Malkonen T, Wikstrom A, Heiskanen K, et al. Skin reactions during anti-TNFalpha therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014 Aug;20(8):1309–1315.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–1451.
   PubMed Web of Science ®Google Scholar
• Hyams J, Dubinsky M, Baldassano R, et al. Risk of malignancy in pediatric inflammatory bowel disease: results from the DEVELOP registry. Gastroenterology. 2016;150(4):S131.
   Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007 Jun 21;356(25):2622–2629.
   PubMed Web of Science ®Google Scholar
• Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol. 1994 Jul 15;153(2):517–528.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):185–191.
   PubMed Web of Science ®Google Scholar
• Linda H, Von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009 Sep 10;361(11):1081–1087.
   PubMed Web of Science ®Google Scholar
• Bellaguarda E, Keyashian K, Pekow J, et al. Prevalence of antibodies against JC virus in patients with refractory Crohn’s disease and effects of natalizumab therapy. Clin Gastroenterol Hepatol. 2015 Nov;13(11):1919–1925.
   PubMed Web of Science ®Google Scholar
• Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Jun;41(12):1227–1236.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2016 Feb 18.
   Web of Science ®Google Scholar
• Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012 Oct 18;367(16):1519–1528.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Gasink C, Blank M, et al. O-001 A multicenter, double-blind, placebo-controlled phase3 study of Ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TNFalpha: UNITI-1. Inflamm Bowel Dis. 2016 Mar;22(Suppl 1):S1.
   PubMedGoogle Scholar
• Cameron FL, Garrick V, Russell RK. Ustekinumab in treatment of refractory paediatric crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(3):e30.
   Google Scholar
• Rigaud D, Cosnes J, Le Quintrec Y, et al. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn’s disease: elemental versus polymeric diet. Gut. 1991 Dec;32(12):1492–1497.
   PubMed Web of Science ®Google Scholar
• Whitten KE, Rogers P, Ooi CY, et al. International survey of enteral nutrition protocols used in children with Crohn’s disease. J Dig Dis. 2012 Feb;13(2):107–112.
   PubMed Web of Science ®Google Scholar
• Meister D, Bode J, Shand A, et al. Anti-inflammatory effects of enteral diet components on Crohn’s disease-affected tissues in vitro. Dig Liver Dis. 2002 Jun;34(6):430–438.
   PubMedGoogle Scholar
• Guzy C, Schirbel A, Paclik D, et al. Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro. Eur J Nutr. 2009 Feb;48(1):12–21.
   PubMed Web of Science ®Google Scholar
• Shah R, Kellermayer R. Microbiome associations of therapeutic enteral nutrition. Nutrients. 2014 Nov;6(11):5298–5311.
   PubMed Web of Science ®Google Scholar
• Schatorje E, Hoekstra H. Transient hypertransaminasemia in paediatric patients with Crohn disease undergoing initial treatment with enteral nutrition. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):336–340.
   PubMed Web of Science ®Google Scholar
• Lemberg DA, Leach ST, Day AS. Transient hypertransaminasemia in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):229.
   PubMed Web of Science ®Google Scholar
• Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014 Feb;146(2):383–391.
   PubMed Web of Science ®Google Scholar